Clariant AG Q2 2026 Earnings Recap

Clariant's shares rose modestly by 2.8% following Q2 results that showed stable sales and margin improvements amid ongoing headwinds from the Middle East conflict. The market appears to have taken a cautiously positive view on pricing actions and cost savings offsetting volume declines, particularly in the Catalysts segment.

Key Takeaways

• Group sales were essentially flat (-0.3% in local currency including portfolio changes; +0.6% on underlying basis).
• Pricing increased 3% across all business units, helping offset inflationary raw material costs.
• Volumes declined 3.3% overall, with a sharp 14.2% drop in Catalysts largely tied to Middle East disruptions.
• EBITDA margin before exceptional items improved by 80 basis points to 18.2%, driven by pricing and volume gains in Care Chemicals and inventory valuation effects.
• Performance improvement programs delivered CHF 10 million savings in Q2, with a raised target of CHF 90 million run rate savings by end-2026, despite restructuring charges of CHF 24 million.